Clinical trials: Typhoid and Paratyphoid Fevers
Typhoid Fever
Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK).
- Trial name
- NCT05613205
- Testing
- TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine
- Where
- Belgium
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid Fever, Paratyphoid Fever
Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study
Enteric fever, an infection characterised by diarrhoea and rash, is most often caused by a bacteria called Salmonella enterica. After ingesting contaminated food or drink, the Salmonellae travel first to the gut, then the…
- Trial name
- NCT02192008
- Testing
- Salmonella Typhi, Salmonella Paratyphi
- Where
- United Kingdom
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Enteric Fever, Acute Febrile Illness
Transcriptomic Responses for the Identification of Pathogens
Acute undifferentiated febrile infection (AUFI) is a common presenting syndrome in low-resource settings and better diagnostics are urgently needed to improve patient management and guide disease prevention interventions.
- Conditions
- Enteric Fever, Acute Febrile Illness, Typhoid, Paratyphoid Fever
- Trial name
- TRiP (NCT04878549)
- Testing
- 5-gene transcription signature
- Where
- India
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Sheffield
Typhoid, Paratyphoid Fever
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125008
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- India
- Volunteers
- 37,673 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid, Paratyphoid Fever
Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125047
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- Pakistan
- Volunteers
- 27,231 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid and Paratyphoid Fevers
TY800 Dose Escalation (Typhoid)
The purpose of this research study is to determine whether a new vaccine for typhoid fever is safe and effective. This study will also look at what effects (good and bad) this new vaccine, Ty800, has on the volunteers.
- Trial name
- NCT00269295
- Testing
- Ty800
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Typhoid, Paratyphoid Fever
Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
This study is part of International Vaccine Institute (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00131833
- Testing
- Typhoid Vi vaccine, Meningococcal A (control)
- Where
- China
- Volunteers
- 96,468 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid, Paratyphoid Fever
Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam
This study is part of International Vaccine Institutes (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00131820
- Testing
- Typhoid Vi vaccine, Hepatitis A (control)
- Where
- Vietnam
- Volunteers
- 100,742 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Enteric Fever Caused by Salmonella Enterica Serovar Paratyphi A
Understanding Paratyphoid Infection
Enteric fever is responsible for over 20 million illnesses and 200,000 deaths each year. S. Paratyphi A accounts for a substantial and increasing proportion of these cases, as high as 90% in some regions of Asia.
- Trial name
- NCT02100397
- Testing
- Salmonella enterica serovar Paratyphi A (strain NVGH308)
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Oxford